Dyslipidemia is a risk factor for the development of cardiovascular disease and one of the most prevalent diseases in the United States. The efficacy of statins has led to their dominance in the market and relegated other drug classes to second- or later-line use. However, drawn by the significant commercial opportunity in this market, pharmaceutical companies have continued drug development efforts in this area, resulting in the launch of seven new agents in the past two years. Using national patient-level claims data, this report analyzes physician adherence to the treatment guidelines by exploring the use of key therapies in the newly diagnosed and recently treated dyslipidemia patient populations. Among the newly diagnosed patients, the report provides a quantitative analysis of treatment patterns and share by line of therapy, as well as progression between lines, duration of treatment on each line, and use of concomitant treatment. Among recently treated patients, the report quantifies a drug’s source of business compared with its competitors and details which drugs precede others through an analysis of add-versus-switch patterns. Additional analyses explore persistency and compliance by brand.